MX394620B - Composicion farmaceutica y metodo para preparar el mismo - Google Patents

Composicion farmaceutica y metodo para preparar el mismo

Info

Publication number
MX394620B
MX394620B MX2019015612A MX2019015612A MX394620B MX 394620 B MX394620 B MX 394620B MX 2019015612 A MX2019015612 A MX 2019015612A MX 2019015612 A MX2019015612 A MX 2019015612A MX 394620 B MX394620 B MX 394620B
Authority
MX
Mexico
Prior art keywords
preparing
same
pharmaceutical composition
solid dispersion
carrier material
Prior art date
Application number
MX2019015612A
Other languages
English (en)
Other versions
MX2019015612A (es
Inventor
Daimei Zhang
Huan Ding
Tingting Zhang
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2019015612A publication Critical patent/MX2019015612A/es
Publication of MX394620B publication Critical patent/MX394620B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una dispersión sólida, un método para prepararla, y una preparación sólida que comprende la dispersión sólida. La dispersión sólida contiene (R)-4-amino-1-(1-(but-2-inoil)pirrolidin-3-il)-3-(4-(2,6-difluorofenoxi)fenil)-1,6-dihidro-7H-pirrolo[2,3-d]piridazin-7-ona o una de sus sales farmacéuticamente aceptables, y un material de soporte. El material de soporte se selecciona de succinato de acetato de hidroxipropilmetilcelulosa y ftalato de hidroxipropilmetilcelulosa.
MX2019015612A 2017-07-04 2018-07-03 Composicion farmaceutica y metodo para preparar el mismo MX394620B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710536705 2017-07-04
CN201711105075 2017-11-10
PCT/CN2018/094211 WO2019007317A1 (zh) 2017-07-04 2018-07-03 一种药物组合物及其制备方法

Publications (2)

Publication Number Publication Date
MX2019015612A MX2019015612A (es) 2020-02-26
MX394620B true MX394620B (es) 2025-03-24

Family

ID=64950432

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015612A MX394620B (es) 2017-07-04 2018-07-03 Composicion farmaceutica y metodo para preparar el mismo

Country Status (15)

Country Link
US (1) US11304945B2 (es)
EP (1) EP3650025A4 (es)
JP (1) JP7190452B2 (es)
KR (1) KR102697985B1 (es)
CN (1) CN109963565B (es)
AU (1) AU2018296476B2 (es)
BR (1) BR112019027473A2 (es)
CA (1) CA3066046A1 (es)
MX (1) MX394620B (es)
MY (1) MY199479A (es)
RU (1) RU2767872C2 (es)
TW (1) TWI837095B (es)
UA (1) UA127413C2 (es)
WO (1) WO2019007317A1 (es)
ZA (1) ZA201908090B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111499642A (zh) * 2019-01-31 2020-08-07 江苏恒瑞医药股份有限公司 吡咯并[2,3-d]哒嗪-7-酮类衍生物的可药用盐、晶型及其制备方法
TW202100527A (zh) 2019-05-31 2021-01-01 大陸商江蘇恆瑞醫藥股份有限公司 一種固體分散體及其製備方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1926476E (pt) * 2005-08-29 2013-07-10 Sanofi Aventis Us Llc Dispersões sólidas amorfas de 7-cloro-n,n,5-trimetil-4-oxo-3- fenil-3,5-di-hidro-4h-piridazino[4,5-b]indole-1-acetamida
JP2010526848A (ja) 2007-05-11 2010-08-05 エフ.ホフマン−ラ ロシュ アーゲー 難溶性薬物用の医薬組成物
JP2013103899A (ja) 2011-11-11 2013-05-30 Fuji Chem Ind Co Ltd 難溶性薬物の新規な固体分散体
MA37711A1 (fr) 2012-06-04 2017-05-31 Pharmacyclics Inc Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
NZ708272A (en) * 2013-01-22 2020-07-31 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
CN105899212A (zh) 2013-08-06 2016-08-24 翁科埃斯克斯有限公司 利用β溴结构域抑制剂治疗弥漫性大B细胞淋巴瘤(DLBCL)的方法
KR102073797B1 (ko) 2014-07-07 2020-02-05 지앙수 헨그루이 메디슨 컴퍼니 리미티드 단백질 키나제 저해제로서의 아미노피리다지논 화합물
US9545407B2 (en) * 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
MX2017011469A (es) 2015-03-10 2018-01-23 Shionogi Inc Dispersiones sólidas.

Also Published As

Publication number Publication date
UA127413C2 (uk) 2023-08-16
TW201906609A (zh) 2019-02-16
US20200171031A1 (en) 2020-06-04
MY199479A (en) 2023-11-01
AU2018296476B2 (en) 2023-11-02
RU2767872C2 (ru) 2022-03-22
BR112019027473A2 (pt) 2020-07-07
JP7190452B2 (ja) 2022-12-15
RU2020102280A3 (es) 2021-09-17
KR102697985B1 (ko) 2024-08-23
TWI837095B (zh) 2024-04-01
KR20200024237A (ko) 2020-03-06
CN109963565A (zh) 2019-07-02
ZA201908090B (en) 2021-08-25
RU2020102280A (ru) 2021-08-04
CN109963565B (zh) 2021-09-03
EP3650025A4 (en) 2021-04-28
JP2020525415A (ja) 2020-08-27
AU2018296476A1 (en) 2020-01-16
WO2019007317A1 (zh) 2019-01-10
EP3650025A1 (en) 2020-05-13
MX2019015612A (es) 2020-02-26
CA3066046A1 (en) 2019-01-10
US11304945B2 (en) 2022-04-19

Similar Documents

Publication Publication Date Title
ZA201902053B (en) Pharmaceutical composition
MX2020012969A (es) Combinacion y composicion farmaceutica y preparacion combinada que contiene activador de glucocinasa y farmaco hipoglucemico biguanida, asi como metodo de preparacion y uso del mismo.
EP3753943A4 (en) HETEROCYCLIC COMPOUND, ITS APPLICATION AND PHARMACEUTICAL COMPOSITION CONSISTING OF IT
MX384545B (es) Composicion farmaceutica
MX2016012058A (es) 2-(2,4-difluorofenil)-1,1-difluoro-1-(5-sustituido-piridin-2-il)- 3-(1h-tetrazol-1-il)propan-2-oles y procedimientos para su preparacion.
MX2021010022A (es) Composicion farmaceutica.
ZA201902052B (en) Pharmaceutical composition
ZA201902049B (en) Pharmaceutical composition
EP3845528C0 (en) PYRAZOLE COMPOUNDS, CORRESPONDING PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AS IRAK4 INHIBITORS
MY190849A (en) Methods of treating multiple sclerosis
EP3882247A4 (en) SIX-MEMBERED, SIX-MEMBERED, HETEROCYCLIC COMPOUND AND USES OF THEREOF AS A PROTEIN KINASE RECEPTOR INHIBITOR
PH12020550125A1 (en) Crystalline forms of 3-substituted 1,2,4-oxadiazole
MX2018015872A (es) Derivados de benzodioxano y su uso farmaceutico.
MX2018013573A (es) Ciertos inhibidores de la proteína cinasa.
GB2590189B (en) Lycorine derivative, and pharmaceutical composition and use thereof
UY30121A1 (es) Nuevos compuestos
MX2020002505A (es) Compuestos heteroaromaticos sustituidos con cicloolefinas y su uso.
EP3838897A3 (en) (hetero)arylamide compound for inhibiting protein kinase activity
MX2023001805A (es) Formas solidas de 2-(5-(4-(2-morfolinoetoxi)fenil)piridin-2-il)-n- bencilacetamida.
MY199479A (en) Pharmaceutical composition and method for preparing same
JOP20210063A1 (ar) مشتقات جديدة من أمينو- بيريميدونيل- بيبريدينيل، وعملية لتحضيرها وتركيبات صيدلانية تحتوي عليها
WO2017046228A3 (en) Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof
ZA201804663B (en) C-glycoside derivatives having fused phenyl ring or pharmaceutically acceptable salts thereof, method for preparing the same and pharmaceutical composition comprising the same
PH12016500134B1 (en) 1-(piperazin-1-yl) -2- ([1,2,4] triazol -1- yl) - ethanone derivatives
WO2017046227A3 (en) Pharmaceutical association of growth factor receptor agonist and adhesion protein inhibitor for converting a neoplastic cell into a non-neoplastic cell and uses thereof